País: Nueva Zelanda
Idioma: inglés
Fuente: Medsafe (Medicines Safety Authority)
Docetaxel trihydrate 135.7mg equivalent to anhydrous docetaxel 120 mg
REX Medical Ltd
Docetaxel trihydrate 135.7 mg (equivalent to anhydrous docetaxel 120 mg)
120 mg/mL
Concentrate for infusion
Active: Docetaxel trihydrate 135.7mg equivalent to anhydrous docetaxel 120 mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection
Vial, glass, Diluent, 9 mL
Prescription
Prescription
Cipla Ltd
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.
Package - Contents - Shelf Life: Vial, glass, Diluent - 9 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 120 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
2006-06-23